Hot Investor Mandate: VC Firm Invests in USA-Based Medical Device & Diagnostics Companies With Established Proof of Concept and Working Prototype

1 Dec

A Venture Capital firm based in USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global VC Invests in Therapeutics and Medical Technologies With Strong Interest in Oncology, Immunology, and Rare Diseases

1 Dec

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Seed Fund Actively Seeks Opportunities in Software-Based Healthcare Companies, Including Digital Health, Diagnostics, R&D Services

1 Dec

A seed fund focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Multi-Family Office Backed Venture Fund Invests in Medical Technology and Lab Equipment, With Strong Interest In Western USA-Based Companies

1 Dec

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. In the recent past, the firm has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

LSN Announces Collaboration with California Life Sciences at RESI JPM San Francisco

17 Nov

By Alexander Vassallo, Manager of Business Development West Coast (US), Entrepreneurial Education Lead, LSN

Last week, Life Science Nation (LSN) was happy to announce a first-of-its-kind collaboration with California Life Sciences (CLS), in the buildup to our next in-person RESI, taking place Jan 10-12, 2023 in San Francisco, during JP Morgan Healthcare week. The collaboration with CLS, who will be featured as a Title Sponsor, will bring into the spotlight many of the elite technology assets emerging from the state’s most impactful life sciences trade association. Over the past nine years, their FAST advisory program has seen 12 exits, 9 acquisitions, and 3 IPOs, with over $2.5B investment secured across all fundraising rounds.

RESI JPM San Francisco, which will see over 500 investors and licensing partners and 350 fundraising executives congregate during JPM week at the Marines Memorial Hotel, is an excellent event to begin the collaboration. CLS will also be featuring 8 early-stage firms across the biotech and medtech sectors in the Innovator’s Pitch Challenge (IPC) at RESI San Francisco as part of the CLS Innovation Track which will serve to further the visibility and growth of these fundraising firms with LSN’s global partner network.

CLS is hosting a networking reception during JPM, a chance to network with the CLS community, including the companies pitching at RESI. Registering for this networking event can be done through the link below.

CLS Reception at JPM: January 11, 2023 | 5:30-7:30PM | The Olympic Club

Led by Sibylle Hauser, Executive Director of Innovation and Entrepreneurship at CLS, and Alex Vassallo, Business Development Manager (West Coast) & Entrepreneurial Education Lead at LSN, this collaboration will serve to strengthen the relationship between the two organizations as the industry moves into 2023. As LSN’s first Strategic Global Tech Hub Partner, CLS is well-positioned to continue fostering the growth of their early-stage life science community and help bring innovative technologies to the market which will hopefully one day change the current paradigms of healthcare.

RESI-SF-2023-Banner-1100-wide

Join These Global Investors at RESI JPM San Francisco 2023

17 Nov

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

After a successful RESI Boston this fall, we are looking forward to bringing together more investors, strategic partners and early-stage, life science and healthcare companies from around the globe at our next in-person event, RESI JPM San Francisco, in the coming year. Whether you plan to travel to San Francisco in-person or participate virtually, RESI will be a great opportunity to kick off your business development or fundraising campaign for 2023.

With the conference starting in less than 2 months, our investor research team has been receiving a great deal of interest from investors every day, including both domestic investors and those based outside of the US. We are expecting 500+ global investors to join this conference, including large pharma/medtech, traditional VCs, family offices/private wealth, and angel groups.

Check out the registered investors for RESI SF below:

CI-11172022

Check RESI Website to See More Confirmed Investors

RESI-SF-2023-Banner-1100-wide

Tech Hub Exposure at RESI 2023

17 Nov

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI JPM San Francisco will be in-person, January 10, followed by two-days of virtual partnering January 11 & 12. If you’re part of a tech hub, Life Science Nation (LSN)’s RESI is the hot spot for meeting with players in the earliest stages of the life science industry.

A key part of RESI is a global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship journey. Recently, RESI has hosted tech hubs ranging from National Institute of Aging (NIA), Brisbane Economic Development Agency (BEDA), California Life Sciences (CLS), Massachusetts Medical Device Development Center (M2D2), Government of Ontario, and more.

Through RESI partnership, tech hub affiliated startups gain access to resources beyond partnering with investors and strategic partners. Resources such as the LSN Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneural Courses. These tools help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.

At RESI San Francisco, tech hub organizations and their startups who’ve raised less than $2M can utilize:

  • 50% discount for startup registration (startup must be from LSN’s tech hub partners)
  • Complimentary tech hub staff registration
  • Exhibition space

If you’re a member of a tech hub or looking to add value to your members, reach out to see which offerings best fit your needs. From lab to clinic, and providers to patients, LSN is accelerating the growth and success of companies emerging from tech hubs.

For more information please contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN.

RESI-SF-2023-Banner-1100-wide

← Older Entries
Newer Entries →